Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial

Cancer Science
Ming LuXiaodong Zhang

Abstract

Nimotuzumab (N) is a humanized anti-epidermal growth factor receptor monoclonal antibody. This prospective, single-armed, open label phase II study was conducted to evaluate the efficacy and safety of the combination of paclitaxel (T)/cisplatin (P) with nimotuzumab (N) as first-line treatment in advanced esophageal squamous cell carcinoma (ESCC). Patients with pathologic confirmed unresectable locally advanced or metastatic ESCC were treated with the TPN regimen: nimotuzumab 200 mg weekly, paclitaxel 175 mg/m(2) on day 1 and cisplatin 30 mg/m(2) on days 1 and 2; repeat cycle every 3 weeks for six cycles. Radiotherapy was allowed to be admitted after four cycles of TPN treatment. The primary endpoint was the objective response rate (ORR). The secondary endpoint was the overall survival (OS), duration of disease control (DDC) and toxicities. From March 2011 to April 2013, a total of 59 patients were enrolled and 56 were eligible for the final analysis. Overall RR was 51.8% and disease control rate (DCR) (CR + PR + SD) was 92.9%. Local treatment (radiotherapy or surgery) followed by chemotherapy improved the duration of disease control for patients with metastatic disease and local-regional advanced disease to 8.2 months and more ...Continue Reading

References

Jul 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H BleibergT Sahmoud
May 20, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D H IlsonD P Kelsen
Oct 31, 2003·Cancer Treatment Reviews·David H Ilson
May 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tania CrombetAgustín Lage
Sep 15, 2005·International Journal of Cancer. Journal International Du Cancer·Mitsuhiko HanawaAkishi Ooi
Apr 1, 2008·American Journal of Clinical Oncology·Xiaodong ZhangMaolin Jin
Oct 9, 2008·Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus·Y FujitaN Tanigawa
Dec 3, 2008·Cancer Chemotherapy and Pharmacology·Youling GongYuquan Wei
Jan 21, 2010·Japanese Journal of Clinical Oncology·Ping ZhaoNi Li

❮ Previous
Next ❯

Citations

Nov 9, 2017·Antioxidants & Redox Signaling·Xiaofei ChenCristina M Furdui
Apr 10, 2018·Monoclonal Antibodies in Immunodiagnosis and Immunotherapy·Mika K KanekoYukinari Kato
Aug 3, 2017·Journal of Experimental & Clinical Cancer Research : CR·Masahiro YoshiokaManabu Muto
Feb 6, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Jun WangYu Liu
Nov 29, 2017·The Cochrane Database of Systematic Reviews·Vincent T JanmaatManon Cw Spaander
Aug 22, 2020·Expert Review of Anticancer Therapy·Hiroshi Imazeki, Ken Kato
Jan 13, 2019·Targeted Oncology·Zhuanglin LiChangjiang Huang
Aug 15, 2020·Frontiers in Oncology·Wen-Qi CaiHong-Wu Xin
Jan 25, 2017·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Xinghua HanJianming Xu
Oct 10, 2020·Expert Opinion on Pharmacotherapy·Chengwei Peng, Deirdre J Cohen

❮ Previous
Next ❯

Methods Mentioned

BETA
pregnancy
contraception

Clinical Trials Mentioned

NCT01336049

Related Concepts

Related Feeds

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.